$ATEX

Ashe Gena L sold $1.4M of ATEX

Ashe Gena L (Chief Legal Officer & Corp Sec) sold 17,711 shares of Anterix Inc. (ATEX) at an average of $81.31 ($81.04–$82.14, $1.44M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Ashe Gena L
Published Jun 17, 2026, 11:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the June 15 open-market sale by the Chief Legal Officer totaling ~$1.44M; no other company events (earnings, guidance, contracts, litigation) are included.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

Insider sales can be driven by diversification, tax, or personal liquidity needs; the article provides no stated reason or broader insider-trading pattern.

Relevance 6/10Novelty 3/10Timing: Filed June 17; sale executed June 15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix (ATEX) insider Form 4 shows Chief Legal Officer Ashe Gena L sold 17,711 shares for about $1.44M at ~$81–$82.

Expected impact

Limited near-term impact; any effect is likely short-lived unless follow-on selling is disclosed.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific catalyst in the text.

Market effects

No sector-level read-through provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the insider sale is not explicitly tied to a pre-arranged 10b5-1 plan, some traders may view it as a stronger negative signal than typical routine sales.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure; ticker ATEX.

  • Ashe Gena L

    Chief Legal Officer & Corp Sec who sold 17,711 shares on June 15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2